首页> 外文期刊>Science >A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses
【24h】

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

机译:引发广泛中和抗体反应的通用HIV疫苗设计策略

获取原文
获取原文并翻译 | 示例
       

摘要

Vaccine induction of broadly neutralizing antibodies (bnAbs) to HIV remains a major challenge. Germline-targeting immunogens hold promise for initiating the induction of certain bnAb classes; yet for most bnAbs, a strong dependence on antibody heavy chain complementarity-determining region 3 (HCDR3) is a major barrier. Exploiting ultradeep human antibody sequencing data, we identified a diverse set of potential antibody precursors for a bnAb with dominant HCDR3 contacts. We then developed HIV envelope trimer-based immunogens that primed responses from rare bnAb-precursor B cells in a mouse model and bound a range of potential bnAb-precursor human naive B cells in ex vivo screens. Our repertoire-guided germline-targeting approach provides a framework for priming the induction of many HIV bnAbs and could be applied to most HCDR3-dominant antibodies from other pathogens.
机译:疫苗对HIV的广泛中和抗体(bnAb)的诱导仍然是一个重大挑战。靶向生殖细胞的免疫原有望引发某些bnAb类的诱导。然而,对于大多数bnAb而言,对抗体重链互补决定区3(HCDR3)的强烈依赖是主要障碍。利用超深层人类抗体测序数据,我们鉴定了具有显性HCDR3接触的bnAb的多种潜在抗体前体。然后,我们开发了基于HIV包膜三聚体的免疫原,该免疫原引发了小鼠模型中罕见的bnAb前体B细胞的应答,并在离体筛选中结合了一系列潜在的bnAb前体人类幼稚B细胞。我们的库指导的种系靶向方法为引发许多HIV bnAb的诱导提供了框架,并且可以应用于来自其他病原体的大多数HCDR3优势抗体。

著录项

  • 来源
    《Science》 |2019年第6470期|1216-1216|共1页
  • 作者单位

    Scripps Res Inst Dept Immunol & Microbiol La Jolla CA 92037 USA|Scripps Res Inst IAVI Neutralizing Antibody Ctr La Jolla CA 92037 USA|Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA;

    Ragon Inst Massachusetts Gen Hosp Massachusetts I Cambridge MA 02139 USA;

    Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA|La Jolla Inst Immunol Div Vaccine Discovery La Jolla CA 92037 USA;

    Scripps Res Inst IAVI Neutralizing Antibody Ctr La Jolla CA 92037 USA|Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA|Scripps Res Inst Dept Integrat Struct & Computat Biol La Jolla CA 92037 USA;

    Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA;

    Scripps Res Inst Dept Immunol & Microbiol La Jolla CA 92037 USA|Scripps Res Inst IAVI Neutralizing Antibody Ctr La Jolla CA 92037 USA|Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA|Wistar Inst Anat & Biol Vaccine & Immune Therapy Ctr 3601 Spruce St Philadelphia PA 19104 USA;

    Scripps Res Inst IAVI Neutralizing Antibody Ctr La Jolla CA 92037 USA|Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA|Scripps Res Inst Ctr Viral Syst Biol La Jolla CA 92037 USA;

    Scripps Res Inst IAVI Neutralizing Antibody Ctr La Jolla CA 92037 USA|Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA|Scripps Res Inst Dept Integrat Struct & Computat Biol La Jolla CA 92037 USA|Scripps Res Inst Skaggs Inst Chem Biol La Jolla CA 92037 USA;

    Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA|Univ Calif San Diego Dept Med Div Infect Dis La Jolla CA 92037 USA;

    Ragon Inst Massachusetts Gen Hosp Massachusetts I Cambridge MA 02139 USA|Harvard Med Sch Dept Immunol Boston MA 02115 USA;

    Scripps Res Inst Dept Immunol & Microbiol La Jolla CA 92037 USA|Scripps Res Inst IAVI Neutralizing Antibody Ctr La Jolla CA 92037 USA|Scripps Res Inst Consortium HIV AIDS Vaccine Dev La Jolla CA 92037 USA|Ragon Inst Massachusetts Gen Hosp Massachusetts I Cambridge MA 02139 USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 05:17:17

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号